View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, May 11 (HealthDay News) -- Use of proton pump inhibitors (PPIs), but not histamine 2 receptor antagonists (H2RAs), is associated with an increased risk of fracture, according to a meta-analysis published in the May/June issue of the Annals of Family Medicine.
Chun-Sick Eom, M.D., M.P.H., from the Seoul National University College of Medicine in South Korea, and colleagues analyzed literature published through 2010 to evaluate the association between the use of PPIs and H2RAs and fracture risk. Five case-control studies, three nested case-control studies, and three cohort studies were included in the meta-analysis.
The investigators found that, compared to nonuse of the respective medications, overall use of PPIs was correlated with a significantly increased risk of any fracture (pooled odds ratio (OR), 1.29), whereas use of H2RAs was not correlated with an increased fracture risk. Long-term H2RA use was not significantly associated with fracture risk but long-term use of PPIs increased the risk of any fracture (adjusted OR, 1.30) and hip fracture (adjusted OR, 1.34).
"In this meta-analysis of observational studies, we found that the use of PPIs was associated with a moderate increase in the risk of fracture compared with nonuse of PPIs, whereas we did not observe any significant association between H2RA use and this risk," the authors write.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top